

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES

First day of trading in Silex's ordinary shares on Nasdaq Stockholm

Silex Microsystems AB ("Silex" or the "Company"), the leading pure-play MEMS foundry globally(1), today announces the outcome of the offering (the "Offering") and listing of its ordinary shares on Nasdaq Stockholm (the "IPO" or the "Listing"). The Offering attracted very strong interest from Swedish and international institutional investors as well as the general public in Sweden and Finland. The Offering was oversubscribed several times. Trading on Nasdaq Stockholm commences today, 7 May 2026.

The Offering in brief

- As previously announced, the price per ordinary share in the Offering was SEK 81 per share (the "**Offer Price**"), equivalent to a valuation of approximately SEK 8,896 million (representing the total market value of all ordinary shares in the Company after the IPO).
- The Offering comprised of 24,595,425 ordinary shares, corresponding to approximately 22.4 percent of the total number of ordinary shares and approximately 22.2 percent of the total number of votes in Silex following settlement of the Offering, of which 12,345,679 ordinary shares were newly issued ordinary shares in Silex and 12,249,746 ordinary shares were existing ordinary shares offered by the selling shareholder Global Access Electronics Ltd. (the "**Selling Shareholder**"), a wholly-owned subsidiary of Sai MicroElectronics Inc. ("**SMEI**").
- Following settlement of the Offering, SMEI's ownership in the Company will amount to approximately 9.9 percent of the outstanding ordinary shares in the Company. Before the Offering and before the transfer of ordinary shares to Bure Equity AB (publ) (the "**IPO Transfer Shares**"), SMEI's holding in the Company amounted to approximately 45.2 percent of the Company's outstanding ordinary shares. Further information regarding SMEI's reduced shareholding in connection with the Offering, and the IPO Transfer Shares, is provided in the prospectus.
- Following settlement of the Offering, Bure Equity AB (publ) will hold approximately 34.2 percent of the outstanding ordinary shares in Silex. Of these, the IPO Transfer Shares represents approximately 19.1 percent of the outstanding ordinary shares in Silex. Excluding the IPO Transfer Shares, Bure Equity AB (publ)'s holding thus amounts to approximately 15.1 percent of the outstanding ordinary shares in Silex.
- In accordance with the terms governing the IPO Transfer Shares, Bure Equity AB (publ) shall, at SMEI's request, resell the IPO Transfer Shares within a period of three years following settlement of the Offering. Following settlement of the Offering, Creades AB (publ)'s holding will correspond to approximately 10.1 percent of the outstanding ordinary

shares in the Company. Furthermore, the combined holdings of Grenspecialisten, Salénia, SEB-Stiftelsen, Tham Special Investment, and TomEnterprise will, following settlement of the Offering, amount to approximately 18.8 percent of the outstanding ordinary shares in the Company.

- In connection with the Offering, the Selling Shareholder, Beijing Silex International Technology Co. Ltd, a wholly-owned subsidiary of SMEI, Bure Equity AB (publ), Creades AB (publ), Grenspecialisten, Salénia, SEB-Stiftelsen, Tham Special Investment and TomEnterprise, as well as members of the Board of Directors and Group Management committed to, subject to certain exceptions, not to sell their respective holdings (or otherwise make certain transactions with similar effect) for a certain period after the date of the Listing. The lock-up period is 360 days for Bure Equity AB (publ), Creades AB (publ) and the members of the Board of Directors and Group Management, and 180 days for the Selling Shareholder, Beijing Silex International Technology Co. Ltd, Grenspecialisten, Salénia, SEB-Stiftelsen, Tham Special Investment, TomEnterprise, the Company and the IPO Transfer Shares.
- The issue of new ordinary shares will provide Silex with proceeds of approximately SEK 1,000 million before deduction of transaction costs of approximately SEK 65 million. Silex intends to use the net proceeds for the following purposes, with the estimated allocation and order of priority: finance the establishment of U.S. production capacity through, as its first priority, the acquisition and conversion of an integrated circuit (i.e., semiconductor wafers that have been made into microchips with a built on electronic circuit functionality) fab (“**U.S. IC Fab**”) located on the East Coast of the United States subject to approval from the Committee on Foreign Investment in the United States. The Company will simultaneously evaluate alternative acquisition, greenfield investment and brownfield investment opportunities, with an estimated capital expenditure of approximately SEK 1,400 million, which is expected to be financed through a combination of equity and debt, including proceeds from the Offering. The purpose of the investment is to facilitate a strategic expansion into the U.S. via the acquisition of the target U.S. IC Fab and subsequent conversion, and finance the expansion of cleanroom capacity of approximately 1,500 square meters at the existing 200 mm fab in Järfälla, Sweden, in order to increase capacity by around 35 percent with an estimated capital expenditure of approximately SEK 500 million over the period from 2027 to 2029. The Company will not receive any proceeds from the sale of existing ordinary shares by the Selling Shareholder.
- The total value of the Offering amounted to approximately SEK 1,992 million.
- In connection with the Offering, Silex welcomes approximately 14,000 new shareholders in the Company.
- Creades AB (publ), AFA Insurance, Tredje AP-fonden, one or more funds and/or accounts managed by Capital Research Global Investors, Swedbank Robur Fonder AB, Fjärde AP-fonden, Andra AP-fonden (AP2), Fidelity International and Carnegie Fonder (together the “**Cornerstone Investors**”) have acquired ordinary shares in the Offering corresponding to an aggregate amount of approximately SEK 1,501 million based on a valuation of approximately SEK 8,896 million (representing the total market value of all ordinary shares in the Company after the IPO). The ordinary shares acquired by the Cornerstone Investors represent, in aggregate, approximately 75 percent of the Offering. The Offering does not include an over-allotment option.
- The total number of shares outstanding after the Offering amounts to 119,575,879 shares, of which 109,832,429 are ordinary shares and 9,743,450 are C-shares.[2]

- Trading on Nasdaq Stockholm commences today, 7 May 2026, under the trading symbol (ticker) "SILEX".
- Settlement is expected to take place on 11 May 2026.

Edvard Kälvesten, CEO and founder of Silex, comments:

"Today marks a major and exciting milestone in Silex's history. The listing on Nasdaq Stockholm broadens our ownership base, giving Silex even better opportunities to expand globally and into growing sectors. I am proud of the great interest from both institutional and retail investors. I want to thank our colleagues and customers for their continued dedication to Silex over the years, and I look forward to leading the company into its next chapter as a listed company."

About Silex Microsystems

Silex is the world's leading MEMS foundry as measured by annual revenue generated from MEMS sales in 2025. Silex operates as a pure play MEMS foundry, which is a specialized wafer fabrication facility (a fab) equipped with advanced equipment, technology and processes required to manufacture MEMS. Silex's customers develop designs and then order MEMS from Silex, after which the Company manufactures high-quality and customized MEMS to its customers' specifications. Silex supports its customers throughout the process, from early prototype creation during the customer's development phase to high volume production in the manufacturing phase. Silex is 'pure-play', as it only manufactures MEMS for its customers, and does not offer any of its own MEMS, semiconductor- or chip-related products.

MEMS are often devices that contain both electrical and mechanical functions. MEMS may contain both electronic as well as three-dimensional mechanical or structural components, and they may also contain a data processing unit, such as a microchip (normally manufactured by a dedicated IC foundry), connected to such three-dimensional mechanical or structural component that interacts with the surrounding environment to form a more complete system.

MEMS are used in a broad range of applications in, for example, telecom, consumer, industrial, automotive, medical, defense and aerospace industries. Silex manufactures MEMS for almost every end-use application sector, providing comprehensive solutions for its customers. Silex's customers can be divided into Fabless customers that do not have their own MEMS or chip production, Fab-light customers that undertake some manufacturing in-house and IDMs that develop and produce most of their own chips in their own fabs.

Silex currently operates one production facility in Järfälla, Sweden, which includes one fab utilizing 200 mm wafer production. Silex continues to invest in innovation and capacity expansion at the Järfälla site, with plans to increase cleanroom capacity by 35 percent and increasing the cleanroom from 4,000 to 5,500 square meters.

For the year ended 31 December 2025, Silex's net sales were SEK 1,385 million with an EBIT of SEK 368 million. For the first quarter of 2026, net sales amounted to SEK 375 million, with an EBIT of SEK 128 million.

Advisors

ABG Sundal Collier AB, Skandinaviska Enskilda Banken AB and Nordea Bank Abp, filial i Sverige are Joint Global Coordinators and Joint Bookrunners in the Offering. Avanza Bank AB (publ), in cooperation with Kepler Cheuvreux, is acting as Joint Bookrunner in the Offering. White & Case is legal advisor to the Company. MAQS Advokatbyrå AB is legal advisor to the Selling Shareholder. Cederquist is legal advisor to the Joint Global Coordinators and Joint Bookrunners.

For further information, please contact:

Erica Falsen, VP Corporate Marketing, Silex Microsystems

Email: press@silex.se

Important information

This announcement is not an offer to sell or a solicitation of any offer to buy any securities issued by Silex Microsystems AB (the “**Company**”) in any jurisdiction where such offer or sale would be unlawful.

Any offering of the securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (together with any related implementing and delegated regulations, the “**Prospectus Regulation**”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.

In any EEA Member State other than Sweden, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation.

This document and the information contained herein are not for distribution in or into the United States of America. This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States. Any securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States.

In the United Kingdom, this document and any other materials in relation to the securities described herein are only being distributed to, and are only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” within the meaning of paragraph 15 of Schedule 1 of the Public Offers and Admissions to Trading Regulations 2024 and that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “**Order**”) or (ii) high net worth entities, and other persons to whom this

announcement may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “**Relevant Persons**”). This communication must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this communication relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so.

Forward-looking statements

Matters discussed in this announcement contain statements that are, or may be deemed to be, forward-looking statements. Forward-looking statements are statements that include matters that are not historical facts or that may not otherwise be provable by reference to past events and may be identified by words such as “believe”, “expect”, “anticipate”, “intend”, “may”, “plan”, “estimate”, “will”, “should”, “could”, “aim” or “might”, or, in each case, their negative, or other variations or comparable terminology, or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. The forward-looking statements in this announcement are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these forward-looking statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. The Company does not guarantee that the assumptions underlying the forward-looking statements in this announcement are free from errors nor does it accept any responsibility for the future accuracy of the opinions expressed in this announcement or any obligation to update or revise the statements in this announcement to reflect subsequent events or circumstances. Readers are advised to view the forward-looking statements contained in this announcement with caution. The forward-looking statements contained in this announcement are based on the views and assumptions of the Company’s management and the facts known by the Company’s management as at the date of the announcement and are subject to change without notice. The Company does not undertake any obligation to review, update, confirm or release publicly any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement.

Please note that an investment in the Company is subject to regulation in accordance with the Swedish Foreign Direct Investment Screening Act (2023:560) (Sw. *lag (2023:560) om granskning av utländska direktinvesteringar*), which requires investors, under certain conditions, to notify and obtain approval from the Inspectorate of Strategic Products (Sw. *Inspektionen för strategiska produkter*). Investors should make their own assessment of whether a notification requirement applies prior to making any investment decision regarding the securities referred to in the prospectus.

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("**MiFID 2**"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID 2; and (c) local implementing measures (together, the "**MiFID 2 Product Governance Requirements**"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the Product Governance Requirements) may otherwise have with respect thereto, the shares have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID 2; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID 2 (the "**Target Market Assessment**"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the shares may decline and investors could lose all or part of their investment; the shares offer no guaranteed income and no capital protection; and an investment in the shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Offering. Furthermore, it is noted that, notwithstanding the Target Market Assessment, the Managers will only procure investors who meet the criteria of professional clients and eligible counterparties. For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID 2; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares. Each distributor is responsible for undertaking its own target market assessment in respect of the shares and determining appropriate distribution channels.

[1] As measured by annual revenue generated from MEMS sales in 2025, source: Company Data Analysis.

[2] The C-shares may be converted into ordinary shares in Q4 2028 if Sillex' share price exceeds a certain level. Please refer to the prospectus for further information.